Oncologia Medica Ospedale di Prato
Welcome,         Profile    Billing    Logout  
 5 Trials 
6 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Biganzoli, Laura
POLAR, NCT03820830 / 2018-003553-19: Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer

Recruiting
3
400
Europe
Palbociclib 125mg, Ibrance, PD-0332991, Standard endocrine therapy
ETOP IBCSG Partners Foundation, Pfizer
Breast Cancer Recurrent
12/24
11/26
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen Inc., Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
05/25
10/27
TOUCH, NCT03644186 / 2017-005067-40: To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer

Completed
2
144
Europe
Paclitaxel, Paclitaxel Sandoz, Trastuzumab, Herceptin, Pertuzumab, Perjeta, Palbociclib, Ibrance, Letrozole, Femara
ETOP IBCSG Partners Foundation, Pfizer, Hoffmann-La Roche
Breast Cancer, Estrogen Receptor Positive Tumor, HER2-positive Breast Cancer
01/23
04/23
FACILE, NCT03944434 / 2018-002514-12: FeAsibility of First-line riboCIclib in oLdEr Patients With Advanced Breast Cancer

Active, not recruiting
2
116
Europe
Ribociclib, Kisqali, Aromatase Inhibitors, non steroideal, Femara, Arimidex, LHRH agonist, Triptorelin, Leuprolide, Goserelin
Fondazione Sandro Pitigliani, Novartis
Breast Cancer
12/24
11/25
PREcoopERA, NCT05896566: A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer

Recruiting
2
220
Europe
Giredestrant, Triptorelin, Anastrozole
ETOP IBCSG Partners Foundation, Hoffmann-La Roche
Breast Cancer
06/26
06/26
NCT06363812: Probability of OncotypeDx to Reallocate as Low or High Risk of Recurrence Breast Cancer Patients With Uncertain Biology

Active, not recruiting
N/A
258
Europe
Fondazione Sandro Pitigliani, Genomic Health®, Inc., Istituto Toscano Tumori
Breast Cancer
05/21
12/24

Download Options